10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2010 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2010 10-K (Filed: Feb 28, 2011) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | |
| Operating activities: | |||
| Net income | $ 2,889,749 | 2,625,592 | 1,970,335 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation expense | 67,240 | 64,560 | 51,722 |
| Amortization expense | 198,237 | 148,384 | 103,888 |
| Purchased in-process research and development expense | 10,851 | ||
| Stock-based compensation expenses | 200,041 | 180,684 | 153,364 |
| In-process research and development impairment | 136,000 | ||
| Excess tax benefits from stock-based compensation | (81,620) | (80,186) | (191,939) |
| Tax benefits from employee stock plans | 82,086 | 88,368 | 209,519 |
| Deferred income taxes | 12,152 | (42,013) | (24,969) |
| Other non-cash transactions | 10,408 | 64,456 | (11,257) |
| Changes in operating assets and liabilities: | |||
| Accounts receivable, net | (348,875) | (356,462) | (257,161) |
| Inventories | (161,190) | (75,266) | (330,726) |
| Prepaid expenses and other assets | (70,466) | (65,667) | 9,719 |
| Accounts payable | (4,453) | 203,641 | 312,568 |
| Income taxes payable | (185,733) | 166,334 | (23,887) |
| Accrued liabilities | 120,065 | 109,026 | 136,276 |
| Deferred revenues | (29,728) | 48,603 | 25,081 |
| Net cash provided by operating activities | 2,833,913 | 3,080,054 | 2,143,384 |
| Investing activities: | |||
| Purchases of marketable securities | (5,502,687) | (2,614,046) | (3,273,112) |
| Proceeds from sales of marketable securities | 3,033,893 | 1,440,509 | 3,026,459 |
| Proceeds from maturities of marketable securities | 683,927 | 435,510 | 193,690 |
| Acquisitions, net of cash acquired | (91,000) | (1,247,816) | (10,851) |
| Capital expenditures and other | (61,884) | (230,057) | (115,005) |
| Net cash used in investing activities | (1,937,751) | (2,215,900) | (178,819) |
| Financing activities: | |||
| Proceeds from issuances of convertible notes, net of issuance costs | 2,462,500 | ||
| Proceeds from sale of warrants | 155,425 | ||
| Purchases of convertible note hedges | (362,622) | ||
| Proceeds from credit facility | 500,000 | 400,000 | |
| Repayments of credit facility | (500,000) | (400,000) | |
| Proceeds from issuances of common stock | 221,223 | 222,728 | 246,125 |
| Repurchases of common stock | (4,022,593) | (998,495) | (1,969,582) |
| Extinguishment of long-term debt | (305,455) | ||
| Repayments of long-term obligations | (5,786) | (5,648) | (4,326) |
| Excess tax benefits from stock-based compensation | 81,620 | 80,186 | 191,939 |
| Distributions from (to) noncontrolling interest | 131,523 | (44,754) | 61,275 |
| Net cash used in financing activities | (1,338,710) | (1,051,438) | (1,474,569) |
| Effect of exchange rate changes on cash | 77,469 | 940 | 1,220 |
| Net change in cash and cash equivalents | (365,079) | (186,344) | 491,216 |
| Cash and cash equivalents at beginning of period | 1,272,958 | 1,459,302 | |
| Cash and cash equivalents at end of period | 907,879 | 1,272,958 | 1,459,302 |
| Supplemental disclosure of cash flow information: | |||
| Interest paid | 15,748 | 8,990 | 7,388 |
| Income taxes paid | 1,129,577 | 746,224 | 495,544 |
| External Links | |
| GILEAD SCIENCES, INC. (GILD) Fiscal Year 2010 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |